Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Drug transporters can govern the absorption, distribution, metabolism, and excretion of substrate drugs and endogenous substances. Investigations to examine their potential impact to pharmacokinetic (PK) drug‐drug interactions (DDIs) are an integral part of the risk assessment in drug development. To evaluate a new molecular entity as a potential perpetrator of transporters, use of well characterized and/or clinically relevant probe substrates with good selectivity and sensitivity are critical for robust clinical DDI assessment that could inform DDI management strategy in the product labeling. The availability of endogenous biomarkers to monitor transporter‐mediated DDIs in early phases of clinical investigations would greatly benefit downstream clinical plans. This article reviews the state‐of‐the‐art in transporter clinical probe drugs and emerging biomarkers, including current challenges and limitations, delineates methods and workflows to identify and validate novel endogenous biomarkers to support clinical DDI evaluations, and proposes how these probe drugs or biomarkers could be used in drug development.

[1]  Whole Grain Label Statements.  Guidance for Industry and FDA Staff , 2006 .

[2]  E. van de Steeg,et al.  Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. , 2012, The Journal of clinical investigation.

[3]  J. Brockmöller,et al.  Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption , 2016, Pain.

[4]  K. Maeda,et al.  Investigation of Endogenous Compounds Applicable to Drug–Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans , 2016, Drug Metabolism and Disposition.

[5]  Yuichi Sugiyama,et al.  Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches , 2018, Clinical pharmacology and therapeutics.

[6]  Hong-Hao Zhou,et al.  Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[7]  Y. Kato,et al.  Concentration-Dependent Effect of Naringin on Intestinal Absorption of β1-Adrenoceptor Antagonist Talinolol Mediated by P-Glycoprotein and Organic Anion Transporting Polypeptide (Oatp) , 2009, Pharmaceutical Research.

[8]  K. Brouwer,et al.  In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.

[9]  M. Hebert,et al.  Pregnancy Increases the Renal Secretion of N1-methylnicotinamide, an Endogenous Probe for Renal Cation Transporters, in Patients Prescribed Metformin , 2017, Drug Metabolism and Disposition.

[10]  A. Galetin,et al.  ITC Commentary on the Prediction of Digoxin Clinical Drug–Drug Interactions from In Vitro Transporter Assays , 2014, Clinical pharmacology and therapeutics.

[11]  Ming-Huei Chen,et al.  Genome-wide association meta-analysis for total serum bilirubin levels. , 2009, Human molecular genetics.

[12]  D. Chinkes,et al.  Isotope Tracers in Metabolic Research: Principles and Practice of Kinetic Analysis , 2004 .

[13]  I. Zineh,et al.  Clinical Drug-Drug Interaction Evaluations to Inform Drug Use and Enable Drug Access. , 2017, Journal of pharmaceutical sciences.

[14]  F. Faltraco,et al.  OCT1 mediates hepatic uptake of sumatriptan and loss‐of‐function OCT1 polymorphisms affect sumatriptan pharmacokinetics , 2016, Clinical pharmacology and therapeutics.

[15]  Lydia M. M. Vermeer,et al.  Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters , 2016, Drug Metabolism and Disposition.

[16]  S. Yoon,et al.  Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans , 2016, Diabetes, obesity & metabolism.

[17]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[18]  O. Langer.  Use of PET Imaging to Evaluate Transporter‐Mediated Drug‐Drug Interactions , 2016, Journal of clinical pharmacology.

[19]  F Müller,et al.  Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin , 2016, Clinical pharmacology and therapeutics.

[20]  Honghui Zhou,et al.  “Cocktail” Approaches and Strategies in Drug Development: Valuable Tool or Flawed Science? , 2004, Journal of clinical pharmacology.

[21]  N. Isoherranen,et al.  Evaluation of 6β‐Hydroxycortisol, 6β‐Hydroxycortisone, and a Combination of the Two as Endogenous Probes for Inhibition of CYP3A4 In Vivo , 2011, Clinical pharmacology and therapeutics.

[22]  K. Giacomini,et al.  The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin , 2016, Clinical Pharmacokinetics.

[23]  K. Giacomini,et al.  ITC Commentary on Metformin Clinical Drug–Drug Interaction Study Design That Enables an Efficacy‐ and Safety‐Based Dose Adjustment Decision , 2018, Clinical pharmacology and therapeutics.

[24]  W. Willmore,et al.  B-vitamin and choline supplementation increases neuroplasticity and recovery after stroke , 2017, Neurobiology of Disease.

[25]  Shiew-Mei Huang,et al.  In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods. , 2017, Journal of pharmaceutical sciences.

[26]  Guideline on the Investigation of Drug Interactions , 2010 .

[27]  Y. Sugiyama,et al.  Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver , 2013, Clinical pharmacology and therapeutics.

[28]  S. Härtter,et al.  Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. , 2012, British journal of clinical pharmacology.

[29]  M. Taub,et al.  The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail. , 2015, Journal of pharmaceutical sciences.

[30]  Jinping Gan,et al.  Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys , 2018, Drug Metabolism and Disposition.

[31]  J. Ware,et al.  Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects , 2018, Journal of clinical pharmacology.

[32]  Prajakti A Kothare,et al.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. , 2014, British journal of clinical pharmacology.

[33]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[34]  M Jamei,et al.  ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans , 2013, Clinical pharmacology and therapeutics.

[35]  K. Maeda,et al.  6β-Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects , 2014, Drug Metabolism and Disposition.

[36]  K. Brouwer,et al.  Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.

[37]  F. Müller,et al.  Biomarkers for In Vivo Assessment of Transporter Function , 2018, Pharmacological Reviews.

[38]  Y. Sugiyama,et al.  Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium , 2018, Clinical pharmacology and therapeutics.

[39]  P. Neuvonen,et al.  Itraconazole decreases renal clearance of digoxin. , 1997, Therapeutic drug monitoring.

[40]  C. Hilgendorf,et al.  Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1 , 2012, Clinical pharmacology and therapeutics.

[41]  H. Zimdahl,et al.  International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms , 2013, Clinical pharmacology and therapeutics.

[42]  C. Gieger,et al.  Human metabolic individuality in biomedical and pharmaceutical research , 2011, Nature.

[43]  Yuichi Sugiyama,et al.  Functional Involvement of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in the Renal Elimination of the Antiviral Drugs Adefovir and Tenofovir , 2007, Molecular Pharmacology.

[44]  L Zhang,et al.  Transporter Studies in Drug Development: Experience to Date and Follow‐Up on Decision Trees From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.

[45]  Kazuya Maeda,et al.  Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[46]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[47]  Kazuya Maeda,et al.  Clarification of the Mechanism of Clopidogrel-Mediated Drug–Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information , 2016, Drug Metabolism and Disposition.

[48]  Kazuya Maeda,et al.  Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans , 2009, Journal of Pharmacology and Experimental Therapeutics.

[49]  R. Kaiser,et al.  Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron , 2010, The Pharmacogenomics Journal.

[50]  X. Chu,et al.  Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. , 2017, Journal of pharmaceutical sciences.

[51]  F. Müller,et al.  N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction , 2014, European Journal of Clinical Pharmacology.

[52]  K. Giacomini,et al.  Transporters Involved in Metformin Pharmacokinetics and Treatment Response. , 2017, Journal of pharmaceutical sciences.

[53]  DL Kroetz,et al.  Metabolomic and Genome‐wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1 , 2016, Clinical pharmacology and therapeutics.

[54]  John Kurhanewicz,et al.  OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin , 2014, Proceedings of the National Academy of Sciences.

[55]  R. Light,et al.  Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. , 2011, Kidney international.

[56]  E. van de Steeg,et al.  Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. , 2010, The Journal of clinical investigation.

[57]  J. Lötsch,et al.  Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol , 2011, Clinical pharmacology and therapeutics.

[58]  F. Müller,et al.  Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions , 2018, British journal of clinical pharmacology.

[59]  Wei Zhang,et al.  Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers , 2013, European Journal of Clinical Pharmacology.

[60]  K. Maeda,et al.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP , 2012, British journal of pharmacology.

[61]  W. Zeng,et al.  Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A , 2017, Clinical pharmacology and therapeutics.

[62]  W. Weber,et al.  System analysis in multiple dose kinetics: Evidence for saturable tubular reabsorption of the organic cationN1-methylnicotinamide in humans , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[63]  A. Nader,et al.  Suitability of digoxin as a P‐glycoprotein probe: Implications of other transporters on sensitivity and specificity , 2014, Journal of clinical pharmacology.

[64]  Lei Zhang,et al.  Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions , 2018, Clinical pharmacology and therapeutics.

[65]  A. Hougaard,et al.  Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine , 2013, Expert opinion on drug metabolism & toxicology.

[66]  Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers , 2016, European Journal of Drug Metabolism and Pharmacokinetics.

[67]  Y Kumagai,et al.  Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects , 2011, Clinical pharmacology and therapeutics.

[68]  Yan Zhang,et al.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance , 2018, Clinical pharmacology and therapeutics.

[69]  Y Kumagai,et al.  Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study , 2011, Clinical pharmacology and therapeutics.

[70]  Wei Zhang,et al.  OATP1B1 POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN‐MEDIATED BILIRUBIN ELEVATION , 2007, Clinical and experimental pharmacology & physiology.

[71]  W. Humphreys,et al.  Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[72]  A. Uitterlinden,et al.  Organic anion transporter 1B1: an important factor in hepatic thyroid hormone and estrogen transport and metabolism. , 2008, Endocrinology.

[73]  W. Humphreys,et al.  Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects , 2017, Drug Metabolism and Disposition.

[74]  H. Kusuhara,et al.  Endogenous Probes for Drug Transporters: Balancing Vision With Reality , 2018, Clinical pharmacology and therapeutics.

[75]  H. Kusuhara,et al.  Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins , 2013, Pharmaceutical Research.

[76]  Caroline A. Lee,et al.  Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design , 2015, Drug Metabolism and Disposition.

[77]  Bo Feng,et al.  Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach , 2017, Drug Metabolism and Disposition.

[78]  R. Altman,et al.  Metformin pathways: pharmacokinetics and pharmacodynamics , 2012, Pharmacogenetics and genomics.

[79]  C Gibson,et al.  Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model‐Based Approaches to Drug–Drug Interaction Trial Design , 2011, Clinical pharmacology and therapeutics.

[80]  L. Aarons,et al.  Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population‐Modeling Approach , 2014, Clinical pharmacology and therapeutics.

[81]  W. Humphreys,et al.  Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[82]  J. Momper,et al.  Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans , 2016, Journal of clinical pharmacology.

[83]  M. Tzvetkov.  OCT1 pharmacogenetics in pain management: is a clinical application within reach? , 2017, Pharmacogenomics.

[84]  N. Vaziri,et al.  Thiamin uptake by the human-derived renal epithelial (HEK-293) cells: cellular and molecular mechanisms. , 2006, American journal of physiology. Renal physiology.

[85]  K. Maeda,et al.  Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers , 2018, Pharmaceutical Research.

[86]  L Zhang,et al.  Predicting transporter‐mediated drug interactions: Commentary on: “Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin” and “Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporte , 2016, Clinical pharmacology and therapeutics.

[87]  Kayode Ogungbenro,et al.  Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation , 2018, Clinical pharmacology and therapeutics.

[88]  X. Chu,et al.  The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist? , 2016, Drug Metabolism and Disposition.

[89]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[90]  L. Zhang,et al.  The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance , 2017, Clinical pharmacology and therapeutics.

[91]  K. Maeda,et al.  Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers , 2017, Pharmaceutical Research.

[92]  F. Faltraco,et al.  Increased Systemic Exposure and Stronger Cardiovascular and Metabolic Adverse Reactions to Fenoterol in Individuals with Heritable OCT1 Deficiency , 2018, Clinical pharmacology and therapeutics.

[93]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[94]  M. Kekki,et al.  Multicompartment analysis of 14C-labelled coproporphyrin and uroporphyrin kinetics in human beings. , 1976, Annals of clinical research.

[95]  Mitchell E Taub,et al.  Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail , 2017, European Journal of Drug Metabolism and Pharmacokinetics.

[96]  Christopher D. Brown,et al.  Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport. , 2017, American journal of human genetics.

[97]  D. Tweedie,et al.  Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P‐gp Inhibition , 2018, Clinical pharmacology and therapeutics.

[98]  M. Monshouwer,et al.  Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions , 2018, Clinical Pharmacokinetics.

[99]  L. Benet,et al.  Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. , 2017, Journal of pharmaceutical sciences.

[100]  A. Ayrton,et al.  Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[101]  M. Weir.  Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. , 2011, Kidney international.

[102]  K. Maeda,et al.  Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. , 2017, Journal of pharmaceutical sciences.

[103]  Lei Zhang,et al.  Evaluation of transporters in drug development: Current status and contemporary issues☆ , 2017, Advanced drug delivery reviews.

[104]  S. Härtter,et al.  Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. , 2013, British journal of clinical pharmacology.

[105]  P. Neuvonen,et al.  Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans , 2009, Pharmacogenetics and genomics.

[106]  H. Kusuhara,et al.  N‐Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2‐K) , 2012, Clinical pharmacology and therapeutics.